Table 4 Belinostat trials reported in 2009 and 2010

Belinostat

Lymphoma

I

9

6SD; tumor shrinkage of 43 and 49% in two patients after cycle 2

Zain et al. (2009)^a

Belinostat

Peripheral/Cutaneous T-cell lymphoma

II

20 (PTCL) n = 29 (CTCL)

PTCL: 2CR, 3PR, 5SD CTCL : 2CR, 2PR, 17SD

Pohlmann et al. (2009)^a

Belinostat

Platinum resitant epithelial ovarian cancer (EOC)+Micropapillary ovarian tumors (LMP)

II

32

1PRu, 10SD (LMP); 9SD (EOC)

Mackay et al. (2010)

Belinostat

Advanced malignant pleural mesothelioma

II

13

2SD; No objective response; 1 death (cardiac arrhythmia)

Ramalingam et al. (2009)

Belinostat

Solid tumors

I

92

33SD

Kelly et al. (2009)^a

Belinostat

Thymic malignancies

II

22

2PR; 13SD

Giaccone et al. (2009)^a